Business Description
Structure Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US86366E1064
Share Class Description:
GPCR: ADRTotal Employee Number:
233Description
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 251.81 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -31.8 | |||||
3-Year EPS without NRI Growth Rate | -23.6 | |||||
3-Year FCF Growth Rate | -46.6 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.07 | |||||
9-Day RSI | 52.79 | |||||
14-Day RSI | 54.12 | |||||
3-1 Month Momentum % | -2.13 | |||||
6-1 Month Momentum % | -50.46 | |||||
12-1 Month Momentum % | 150.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 26.16 | |||||
Quick Ratio | 26.16 | |||||
Cash Ratio | 25.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.8 | |||||
Shareholder Yield % | -0.05 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -15.98 | |||||
ROA % | -15.19 | |||||
ROIC % | -562.96 | |||||
3-Year ROIIC % | -165.35 | |||||
ROC (Joel Greenblatt) % | -1889.59 | |||||
ROCE % | -20.53 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.5 | |||||
Price-to-Tangible-Book | 2.5 | |||||
EV-to-EBIT | -9.83 | |||||
EV-to-EBITDA | -9.91 | |||||
EV-to-FCF | -13.58 | |||||
| Price-to-Net-Current-Asset-Value | 2.53 | |||||
| Price-to-Net-Cash | 2.59 | |||||
Earnings Yield (Greenblatt) % | -10.17 | |||||
FCF Yield % | -4.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GPCR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Structure Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.774 | ||
| Beta | -2.0274 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 1 | ||
| Volatility % | 120.62 | ||
| 14-Day RSI | 54.12 | ||
| 14-Day ATR ($) | 2.773501 | ||
| 20-Day SMA ($) | 51.24725 | ||
| 12-1 Month Momentum % | 150.19 | ||
| 52-Week Range ($) | 15.8 - 94.9 | ||
| Shares Outstanding (Mil) | 71.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Structure Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Structure Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 106 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 14 days | ||
| General meeting for 2026 | 2026-06-17 09:00 | 42.91 (+0.47%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-09 10:00 | 37.77 (+0.80%) | ||
| Guidance call for 2026 | 2026-06-03 12:15 | 37.19 (-2.11%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 40.84 (+0.20%) | ||
| Annual report for 2025 | 2026-02-26 | 66.53 (-3.58%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 66.53 (-3.58%) | ||
| Topline Results from Aleniglipron Phase 2 ACCESS Program | 2025-12-08 08:30 | 34.56 (+4.32%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 32.21 (-5.29%) |
Show
Entries
Structure Therapeutics Inc Frequently Asked Questions
What is Structure Therapeutics Inc(GPCR)'s stock price today?
The current price of GPCR is $50.86. The 52 week high of GPCR is $94.90 and 52 week low is $15.80.
When is next earnings date of Structure Therapeutics Inc(GPCR)?
The next earnings date of Structure Therapeutics Inc(GPCR) is 2026-08-06 Est..
Does Structure Therapeutics Inc(GPCR) pay dividends? If so, how much?
Structure Therapeutics Inc(GPCR) does not pay dividend.
Guru Commentaries on NAS:GPCR
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Qiming Venture Partners Backed Structure Therapeutics Successfully Debuts on Nasdaq | 2023-02-04 |
Articles on Structure Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers